Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Cancer Sci. 2019 Jun;110(6):1897-1908. doi: 10.1111/cas.14026. Epub 2019 May 24.
Xp11.2 translocation renal cell carcinoma (Xp11 tRCC) is a rare sporadic pediatric kidney cancer caused by constitutively active TFE3 fusion proteins. Tumors in patients with Xp11 tRCC tend to recur and undergo frequent metastasis, in part due to lack of methods available to detect early-stage disease. Here we generated transgenic (Tg) mice overexpressing the human PRCC-TFE3 fusion gene in renal tubular epithelial cells, as an Xp11 tRCC mouse model. At 20 weeks of age, mice showed no histological abnormalities in kidney but by 40 weeks showed Xp11 tRCC development and related morphological and histological changes. MicroRNA (miR)-204-5p levels in urinary exosomes of 40-week-old Tg mice showing tRCC were significantly elevated compared with levels in control mice. MicroRNA-204-5p expression also significantly increased in primary renal cell carcinoma cell lines established both from Tg mouse tumors and from tumor tissue from 2 Xp11 tRCC patients. All of these lines secreted miR-204-5p-containing exosomes. Notably, we also observed increased miR-204-5p levels in urinary exosomes in 20-week-old renal PRCC-TFE3 Tg mice prior to tRCC development, and those levels were equivalent to those in 40-week-old Tg mice, suggesting that miR-204-5p increases follow expression of constitutively active TFE3 fusion proteins in renal tubular epithelial cells prior to overt tRCC development. Finally, we confirmed that miR-204-5p expression significantly increases in noncancerous human kidney cells after overexpression of a PRCC-TFE3 fusion gene. These findings suggest that miR-204-5p in urinary exosomes could be a useful biomarker for early diagnosis of patients with Xp11 tRCC.
Xp11.2 易位性肾细胞癌(Xp11 tRCC)是一种罕见的散发性小儿肾肿瘤,由组成性激活的 TFE3 融合蛋白引起。Xp11 tRCC 患者的肿瘤往往会复发并经常发生转移,部分原因是缺乏早期疾病检测方法。在这里,我们在肾小管上皮细胞中过表达人 PRCC-TFE3 融合基因,生成了 Xp11 tRCC 的转基因(Tg)小鼠模型。在 20 周龄时,小鼠肾脏没有组织学异常,但在 40 周龄时出现了 Xp11 tRCC 发展和相关的形态和组织学变化。与对照小鼠相比,显示出 tRCC 的 40 周龄 Tg 小鼠尿液外泌体中的 microRNA(miR)-204-5p 水平显著升高。从 Tg 小鼠肿瘤和 2 名 Xp11 tRCC 患者的肿瘤组织中建立的原发性肾细胞癌细胞系中,miR-204-5p 的表达也显著增加。所有这些细胞系都分泌含有 miR-204-5p 的外泌体。值得注意的是,我们还观察到在 tRCC 发展之前,20 周龄的肾脏 PRCC-TFE3 Tg 小鼠尿液外泌体中的 miR-204-5p 水平升高,并且这些水平与 40 周龄的 Tg 小鼠相当,表明 miR-204-5p 在明显的 tRCC 发展之前,在肾小管上皮细胞中表达组成性激活的 TFE3 融合蛋白后增加。最后,我们证实了在过表达 PRCC-TFE3 融合基因后,非癌性人肾细胞中的 miR-204-5p 表达显著增加。这些发现表明,尿液外泌体中的 miR-204-5p 可能是 Xp11 tRCC 患者早期诊断的有用生物标志物。